Literature DB >> 19539700

Variations in the cannabinoid receptor 1 gene predispose to migraine.

Gabriella Juhasz1, Judit Lazary, Diana Chase, Emma Pegg, Darragh Downey, Zoltan G Toth, Kathryn Stones, Hazel Platt, Krisztina Mekli, Antony Payton, Ian M Anderson, J F William Deakin, Gyorgy Bagdy.   

Abstract

In animal models endogenous cannabinoids have an inhibitory effect on trigeminovascular activation through the cannabinoid receptor 1 (CB1), although there is no evidence of the potential role of CB1 in human migraine. In this study we applied single marker association and haplotypic trend regression analysis to investigate the relationship between the CB1 gene (CNR1) and headache with migraine symptoms (nausea, photophobia and disability, measured by the ID-migraine questionnaire). We identified our controls (CO=684) as those who have not reported ID-migraine symptoms at all and defined migraine headache sufferers (M=195) as those who reported all three symptoms. The CNR1 was covered by 10 SNPs located throughout the gene based on haplotype tagging (htSNP) and previous literature. Our results demonstrated a significant haplotypic effect of CNR1 on migraine headaches (p=0.008, after permutation p=0.017). This effect was independent of reported depression or drug/alcohol abuse although using neuroticism in the analysis as covariant slightly decreased this association (p=0.027, permutated p=0.052). These results suggest a significant effect of CNR1 on migraine headaches that might be related to the alteration of peripheral trigeminovascular activation. In addition, this is the first study to demonstrate the effectiveness of using trait components combinations to define extreme phenotypes with haplotype analysis in genetic association studies for migraine. However, further studies are needed to elucidate the role of CNR1 and the cannabinoid system in migraine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539700     DOI: 10.1016/j.neulet.2009.06.021

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

Review 1.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

2.  Phytomedicines in the Treatment of Migraine.

Authors:  Thilinie Rajapakse; William Jeptha Davenport
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 3.  Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

Authors:  C J Hillard; K M Weinlander; K L Stuhr
Journal:  Neuroscience       Date:  2011-11-17       Impact factor: 3.590

4.  Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia.

Authors:  Shad B Smith; Dylan W Maixner; Roger B Fillingim; Gary Slade; Richard H Gracely; Kirsten Ambrose; Dmitri V Zaykin; Craig Hyde; Sally John; Keith Tan; William Maixner; Luda Diatchenko
Journal:  Arthritis Rheum       Date:  2012-02

5.  The G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients.

Authors:  Mercedes Núñez; Sandra Perdomo; Juan Moreta; Ángel Santos-Briz; Rogelio González-Sarmiento
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

6.  Motion sickness, stress and the endocannabinoid system.

Authors:  Alexander Choukèr; Ines Kaufmann; Simone Kreth; Daniela Hauer; Matthias Feuerecker; Detlef Thieme; Michael Vogeser; Manfred Thiel; Gustav Schelling
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

7.  Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.

Authors:  Ram Kandasamy; Cole T Dawson; Rebecca M Craft; Michael M Morgan
Journal:  Eur J Pharmacol       Date:  2017-10-28       Impact factor: 4.432

Review 8.  Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine.

Authors:  Gábor Nagy-Grócz; Ferenc Zádor; Szabolcs Dvorácskó; Zsuzsanna Bohár; Sándor Benyhe; Csaba Tömböly; Árpád Párdutz; László Vécsei
Journal:  Int J Mol Sci       Date:  2017-07-30       Impact factor: 5.923

9.  Irritable bowel syndrome and migraine: bystanders or partners?

Authors:  Full-Young Chang; Ching-Liang Lu
Journal:  J Neurogastroenterol Motil       Date:  2013-07-08       Impact factor: 4.924

Review 10.  High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity.

Authors:  Marie Fitzgibbon; David P Finn; Michelle Roche
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-05       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.